These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 38806889)
1. Optimizing Solid Tumor Treatment with Antibody-drug Conjugates Using Agent-Based Modeling: Considering the Role of a Carrier Dose and Payload Class. Calopiz MC; Linderman JJ; Thurber GM Pharm Res; 2024 Jun; 41(6):1109-1120. PubMed ID: 38806889 [TBL] [Abstract][Full Text] [Related]
2. An Agent-Based Systems Pharmacology Model of the Antibody-Drug Conjugate Kadcyla to Predict Efficacy of Different Dosing Regimens. Menezes B; Cilliers C; Wessler T; Thurber GM; Linderman JJ AAPS J; 2020 Jan; 22(2):29. PubMed ID: 31942650 [TBL] [Abstract][Full Text] [Related]
3. Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival. Cilliers C; Menezes B; Nessler I; Linderman J; Thurber GM Cancer Res; 2018 Feb; 78(3):758-768. PubMed ID: 29217763 [TBL] [Abstract][Full Text] [Related]
4. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues. Zhang D; Dragovich PS; Yu SF; Ma Y; Pillow TH; Sadowsky JD; Su D; Wang W; Polson A; Khojasteh SC; Hop CECA Drug Metab Dispos; 2019 Oct; 47(10):1146-1155. PubMed ID: 31358513 [TBL] [Abstract][Full Text] [Related]
5. Mechanistic Modeling of Intra-Tumor Spatial Distribution of Antibody-Drug Conjugates: Insights into Dosing Strategies in Oncology. Weddell J; Chiney MS; Bhatnagar S; Gibbs JP; Shebley M Clin Transl Sci; 2021 Jan; 14(1):395-404. PubMed ID: 33073529 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Pharmacodynamics of TAK-164 Antibody Drug Conjugate Coadministered with Unconjugated Antibody. Menezes B; Khera E; Calopiz M; Smith MD; Ganno ML; Cilliers C; Abu-Yousif AO; Linderman JJ; Thurber GM AAPS J; 2022 Oct; 24(6):107. PubMed ID: 36207468 [TBL] [Abstract][Full Text] [Related]
8. Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody-Drug Conjugate Exposure in Solid Tumor. Bussing D; Sharma S; Li Z; Meyer LF; Shah DK AAPS J; 2021 Apr; 23(3):56. PubMed ID: 33856579 [TBL] [Abstract][Full Text] [Related]
9. Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes. Ma Y; Dela Cruz-Chuh J; Khojasteh SC; Dragovich PS; Pillow TH; Zhang D Drug Metab Dispos; 2019 Aug; 47(8):884-889. PubMed ID: 31072822 [TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates. Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709 [TBL] [Abstract][Full Text] [Related]
11. Modeling to capture bystander-killing effect by released payload in target positive tumor cells. Byun JH; Jung IH BMC Cancer; 2019 Mar; 19(1):194. PubMed ID: 30832603 [TBL] [Abstract][Full Text] [Related]
12. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models. Li F; Emmerton KK; Jonas M; Zhang X; Miyamoto JB; Setter JR; Nicholas ND; Okeley NM; Lyon RP; Benjamin DR; Law CL Cancer Res; 2016 May; 76(9):2710-9. PubMed ID: 26921341 [TBL] [Abstract][Full Text] [Related]
13. A Systems Pharmacology Model for Drug Delivery to Solid Tumors by Antibody-Drug Conjugates: Implications for Bystander Effects. Burton JK; Bottino D; Secomb TW AAPS J; 2019 Dec; 22(1):12. PubMed ID: 31828446 [TBL] [Abstract][Full Text] [Related]
14. Antibody drug conjugates beyond cytotoxic payloads. Hobson AD Prog Med Chem; 2023; 62():1-59. PubMed ID: 37981349 [TBL] [Abstract][Full Text] [Related]
15. Antibody-Drug Conjugates with Pyrrole-Based KSP Inhibitors as the Payload Class. Lerchen HG; Wittrock S; Stelte-Ludwig B; Sommer A; Berndt S; Griebenow N; Rebstock AS; Johannes S; Cancho-Grande Y; Mahlert C; Greven S; Terjung C Angew Chem Int Ed Engl; 2018 Nov; 57(46):15243-15247. PubMed ID: 30180286 [TBL] [Abstract][Full Text] [Related]
16. Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody-Drug Conjugates. Schmitt S; Machui P; Mai I; Herterich S; Wunder S; Cyprys P; Gerlach M; Ochtrop P; Hackenberger CPR; Schumacher D; Helma J; Vogl AM; Kasper MA Mol Cancer Ther; 2024 Feb; 23(2):199-211. PubMed ID: 37828728 [TBL] [Abstract][Full Text] [Related]
17. Simulating the Selection of Resistant Cells with Bystander Killing and Antibody Coadministration in Heterogeneous Human Epidermal Growth Factor Receptor 2-Positive Tumors. Menezes B; Linderman JJ; Thurber GM Drug Metab Dispos; 2022 Jan; 50(1):8-16. PubMed ID: 34649966 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer. Malik P; Phipps C; Edginton A; Blay J Pharm Res; 2017 Dec; 34(12):2579-2595. PubMed ID: 28924691 [TBL] [Abstract][Full Text] [Related]
19. Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads. Xi M; Zhu J; Zhang F; Shen H; Chen J; Xiao Z; Huangfu Y; Wu C; Sun H; Xia G Eur J Med Chem; 2024 Oct; 276():116709. PubMed ID: 39068862 [TBL] [Abstract][Full Text] [Related]